Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, N. Caeyers et al.|Annals of the Rheumatic Diseases|2016Cited by 331
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trialsThomas Buttgereit, Frank Buttgereit, Andriko Palmowski et al.|Age and Ageing|2021Cited by 48